Cathepsin B-Cleavable Polymeric Photosensitizer Prodrug for Selective Photodynamic Therapy: In Vitro Studies.
Manish JainJordan BouillouxInes BorregoStéphane CookHubert van den BerghNorbert LangeGeorges WagnieresMarie-Noelle GiraudPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Cathepsin B is a lysosomal cysteine protease that plays an important role in cancer, atherosclerosis, and other inflammatory diseases. The suppression of cathepsin B can inhibit tumor growth. The overexpression of cathepsin B can be used for the imaging and photodynamic therapy (PDT) of cancer. PDT targeting of cathepsin B may have a significant potential for selective destruction of cells with high cathepsin B activity. We synthesized a cathepsin B-cleavable polymeric photosensitizer prodrug (CTSB-PPP) that releases pheophorbide a (Pha), an efficient photosensitizer upon activation with cathepsin B. We determined the concentration dependant uptake in vitro, the safety, and subsequent PDT-induced toxicity of CTSB-PPP, and ROS production. CTSB-PPP was cleaved in bone marrow cells (BMCs), which express a high cathepsin B level. We showed that the intracellular fluorescence of Pha increased with increasing doses (3-48 µM) and exerted significant dark toxicity above 12 µM, as assessed by MTT assay. However, 6 µM showed no toxicity on cell viability and ex vivo vascular function. Time-dependent studies revealed that cellular accumulation of CTSB-PPP (6 µM) peaked at 60 min of treatment. PDT (light dose: 0-100 J/cm 2 , fluence rate: 100 mW/cm 2 ) was applied after CTSB-PPP treatment (6 µM for 60 min) using a special frontal light diffuser coupled to a diode laser (671 nm). PDT resulted in a light dose-dependent reduction in the viability of BMCs and was associated with an increased intracellular ROS generation. Fluorescence and ROS generation was significantly reduced when the BMCs were pre-treated with E64-d, a cysteine protease inhibitor. In conclusion, we provide evidence that CTSB-PPP showed no dark toxicity at low concentrations. This probe could be utilized as a potential imaging agent to identify cells or tissues with cathepsin B activity. CTSB-PPP-based PDT results in effective cytotoxicity and thus, holds great promise as a therapeutic agent for achieving the selective destruction of cells with high cathepsin B activity.
Keyphrases
- photodynamic therapy
- induced apoptosis
- fluorescence imaging
- cell cycle arrest
- oxidative stress
- cell death
- cancer therapy
- bone marrow
- reactive oxygen species
- drug delivery
- dna damage
- endoplasmic reticulum stress
- high resolution
- cardiovascular disease
- squamous cell carcinoma
- gene expression
- signaling pathway
- cell proliferation
- single molecule
- transcription factor
- mesenchymal stem cells
- pi k akt
- working memory
- endothelial cells
- fluorescent probe
- artificial intelligence
- single cell
- squamous cell
- functional connectivity
- case control
- diabetic rats
- high glucose